


CLAIMS


1. A compound having Formula **I-A**:



I-A

or a pharmaceutically acceptable salt or solvate thereof, wherein:

A^1 is selected from the group consisting of:



R^{12c} and R^{12d} are independently selected from the group consisting of hydrogen and optionally substituted C_{1-8} alkyl; or

R^{12c} and R^{12d} taken together with the carbon atom to which they are attached form a 4- to 8-membered optionally substituted cycloalkyl or a 4- to 8-membered optionally substituted heterocyclo;

R^{13} is selected from the group consisting of hydrogen, optionally substituted C_{1-6} alkyl, and heteroalkyl;

R^{17} is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;

R^{22a} is selected from the group consisting of optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, and optionally substituted heteroaryl;

R^{22b} is selected from the group consisting of optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, and optionally substituted heteroaryl;

Q^1 is selected from the group consisting of alkylenyl, phenylenyl, heteroarylenyl, cycloalkylenyl, and heterocyclylenyl;



is a fused optionally substituted phenyl, fused optionally substituted thienyl, fused optionally substituted pyridyl, or fused optionally substituted pyrimidyl group;

R^{a5} , R^{a6} , R^{a11} , and R^{a12} are each independently selected from the group consisting of hydrogen and halo;

R^{a9} and R^{a10} are independently selected from the group consisting of hydrogen, halo, C_{1-4} alkyl, haloalkyl, alkoxy, and haloalkoxy;

R^{a13} is selected from the group consisting of hydrogen, C_{1-4} alkyl, and C_{3-8} cycloalkyl;

L^1 is $-X^1-L^2-Y^1-$;

X^1 is X^2 ; or

X^1 is absent;

X^2 is selected from the group consisting of $-N(H)C(=O)-$, $-C(=O)N(H)-$, $-C(=O)N(H)S(O)_2-$, $-N(H)C(=O)N(H)-$, $-N(H)C(=O)O-$, $-OC(=O)N(H)-$, $-SO_2-$, $-O-$, $-N(H)-$, $-SO_2N(H)-$, $-N(H)SO_2-$, $-CH_2-$, $-CH=CH-$, and $-C\equiv C-$;

L^2 is selected from the group consisting of alkylene, heteroalkylene, $-A^4-(CH_2)_m-W-(CH_2)_n-$ and $-(CH_2)_m-W-(CH_2)_u-O-(CH_2)_v-$; or

L^2 is absent;

A^4 is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or

A^4 is absent;

W is selected from the group consisting of phenylene, 5-membered heteroarylene, 6-membered heteroarylene, heterocyclylene, and cycloalkylene;

m is 0, 1, 2, 3, 4, 5, 6, or 7;

n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;

u is 0, 1, 2, or 3;


v is 1, 2, 3, or 4;

Y^1 is selected from the group consisting of $-C\equiv C-$, $-CH=CH-$, $-CH_2-$, $-O-$, $-N(R^{2b})-$, $-C(=O)N(R^{2c})-$, $-N(R^{2d})C(=O)CH_2O-$, and $-N(R^{2e})C(=O)CH_2N(R^{2f})-$; or

Y^1 is absent;

wherein the carboxamide nitrogen atom of $-N(R^{2d})C(=O)CH_2O-$ and $-N(R^{2e})C(=O)CH_2N(R^{2f})-$, and the carbon atom of $-C(=O)N(R^{2c})-$ is attached to L^2 ;

R^{2a} , R^{2b} , R^{2c} , R^{2d} , R^{2e} , and R^{2f} are each independently selected from the group consisting of hydrogen and C_{1-4} alkyl;



A^{1a} is selected from the group consisting of -C(R^{16a})= and -N=;

A² is selected from the group consisting of -C(R^{16b})= and -N=;

A³ is selected from the group consisting of -C(R^{16c})= and -N=;

G is selected from the group consisting of -C(R^{16d})= and -N=;

Z is selected from the group consisting of -CH₂ and -C(=O)-;

R⁵ is selected from the group consisting of hydrogen, methyl, and fluoro;

R^{16a} is selected from the group consisting of hydrogen, halo, and C₁₋₄

alkyl;

R^{16b} is selected from the group consisting of hydrogen, halo, and C₁₋₄

alkyl;


R^{16c} is selected from the group consisting of hydrogen, halo, and C₁₋₄

alkyl; and

R^{16d} is selected from the group consisting of hydrogen, halo, and C₁₋₄


alkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein A¹ is:




3. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein:

A¹ is:




A-100.

4. The compound of claim 3, or a pharmaceutically acceptable salt or solvate thereof, wherein Q^1 is cycloalkylenyl selected from the group consisting of:



5. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, having Formula VII:




VII,

wherein:

R^{12c} and R^{12d} taken together with the carbon atom to which they are attached form a 4-membered cycloalkyl or 6-membered optionally substituted cycloalkyl;

R^{17} is:



A^{11} is $-C(R^{20c})=$;

R^{20a} , R^{20b} , and R^{20c} are each hydrogen;
 R^{20d} and R^{20e} are independently selected from the group consisting of hydrogen and halo;
 R^{18b} , R^{18c} , and R^{18d} are each independently selected from the group consisting of hydrogen and halo; and
 R^{21a} and R^{21b} are each independently selected from the group consisting of hydrogen, halo, C_{1-4} alkyl, haloalkyl, alkoxy, and haloalkoxy.

6. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein L^2 is C_{1-12} alkylenyl.

7. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein L^2 is 3- to 12-membered heteroalkylenyl.




8. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein:

L^2 is $-A^4-(CH_2)_m-W-(CH_2)_n-$; and

A^4 is absent.

9. The compound of claim 8, or a pharmaceutically acceptable salt or solvate thereof, wherein W is heterocyclenyl.


10. The compound of claim 9, or a pharmaceutically acceptable salt or solvate thereof, wherein L^2 is selected from the group consisting of:




11. The compound of claim 10, or a pharmaceutically acceptable salt or solvate thereof, wherein m is 0, and n is 0 or 1.


12. The compound of claim 11, or a pharmaceutically acceptable salt or solvate thereof, wherein Y¹ is -C≡C-.


13. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein B¹ is selected from the group consisting of:









14. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, selected from the group consisting of:


































;




;




;




;




;




;







;




;




;









;




;




;







;




;




;




;








;





;




;









;




;




;



;



;



;


;


;

;


;

;







;




;




;




;




;



;





;




;


;








2




and







.

15. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, selected from the group consisting of compounds: 19, 31, 32, 50, 56, 147, 173, 175, 194, 220 and 222, namely:



,



(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)pent-4-yn-1-yl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide,

(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-((1R,4R)-4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)pent-4-yn-1-yl)carbamoyl)cyclohexyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide,

(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-(4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)ethynyl)piperidine-1-carbonyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide,

(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)pent-4-yn-1-yl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide,

(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisindolin-5-yl)pent-4-yn-1-yl)carbamoyl)phenyl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide,

(3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(3-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)pent-4-yn-1-yl)carbamoyl)bicyclo[1.1.1]pentan-1-yl)-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide, and

(3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)pent-4-yn-1-yl)carbamoyl)phenyl)-4,4-dimethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide.

16. A pharmaceutical composition comprising the compound of any previous claim, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

17. The compound of any of claims 1 to 15, or a pharmaceutically acceptable salt or solvate thereof, for use in treating cancer, a chronic autoimmune disorder, an inflammatory condition, a proliferative disorder, sepsis, or a viral infection.

18. The compound or a pharmaceutically acceptable salt or solvate thereof for use according to claim 17 in treating cancer.